StockNews.com Downgrades Lantheus (NASDAQ:LNTH) to Hold

StockNews.com downgraded shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a research report report published on Friday morning.

LNTH has been the subject of several other reports. JMP Securities reaffirmed a market outperform rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Truist Financial boosted their price objective on shares of Lantheus from $82.00 to $96.00 and gave the stock a buy rating in a report on Friday. Mizuho increased their target price on Lantheus from $90.00 to $100.00 and gave the company a buy rating in a research note on Friday. Finally, B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the stock a buy rating in a research note on Thursday, April 18th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $99.17.

Lantheus Stock Down 0.0 %

LNTH stock opened at $75.51 on Friday. The business has a 50 day moving average of $62.82 and a 200 day moving average of $62.75. The firm has a market cap of $5.23 billion, a PE ratio of 11.53 and a beta of 0.52. Lantheus has a twelve month low of $50.20 and a twelve month high of $100.85. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. On average, research analysts forecast that Lantheus will post 5.96 EPS for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently bought and sold shares of LNTH. Parkside Financial Bank & Trust increased its stake in Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 156 shares during the last quarter. Prosperity Financial Group Inc. raised its stake in Lantheus by 6.2% during the third quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 173 shares in the last quarter. Shaker Investments LLC OH lifted its position in Lantheus by 0.7% during the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after purchasing an additional 182 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Lantheus by 3.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock worth $432,000 after buying an additional 188 shares in the last quarter. Finally, NBC Securities Inc. increased its holdings in shares of Lantheus by 28.4% in the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 191 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.